We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > SCLC

News List

BMS' Opdivo+Yervoy combo fails in small cell lung cancer pharmafile
November 28, 2018
Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as a maintenance treatment for extensive-stage
KOL Views: How does Opdivo’s stumble shift the balance of power in SCLC? biospectrumasia
October 17, 2018
KOL Views Imfinzi Keytruda Opdivo Tecentriq AstraZeneca BMS Merck & Co. Roche EMA FDA Lung Cancer Pulmonary/Respiratory Medicine Marketing & Sales Medical Affairs
G1 Therapeutics Unveils Positive Mid-Stage Data for Myelopreservation in SCLC Patients biospace
March 06, 2018
A mid-stage program aimed at treating myelosuppression in lung cancer patients undergoing chemotherapy is yielding positive results

Previous page 1 2 Next page